Consonance-HFW Acquisition Corp. (CHFW-UN) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; it offers no current products or services beyond its standard SPAC structure of redeemable units comprising Class A ordinary shares and warrants, with a forward purchase agreement enabling additional sponsor funding at acquisition closing. The company targets the life sciences industry, particularly biotechnology sectors in the United States and Europe. Incorporated in 2020 and headquartered in Princeton, New Jersey, it completed its initial public offering in November 2020, raising approximately $80-92 million at $10 per unit through J.P. Morgan, with NYSE American listing under CHFW.U. Geographically, it pursues targets in developed markets including the U.S. and European countries. In April 2021, it announced a definitive business combination with Surrozen Inc., a Wnt pathway therapeutics developer, involving a $120 million PIPE from life sciences investors and expected $212 million gross proceeds assuming no redemptions, with plans to redomicile to Delaware, rename to Surrozen Inc., and list on Nasdaq as SRZN; the deal, approved by both boards and carrying a $203 million enterprise value, closed in August 2021 via shareholder vote, marking its primary strategic transaction, though CHFW-UN units persist in limited trading as of late 2025 with recent price activity around $9.55.